Stefan Miltenyi

Bergisch Gladbach, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

Journal: Nature medicine

Published: September 30, 2025

Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial.

Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial.

Journal: Nature medicine

Published: September 05, 2025

Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.

Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.

Journal: Blood advances

Published: August 12, 2025

Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial.

Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial.

Journal: Blood advances

Published: August 12, 2025

Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel.

Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel.

Journal: RMD open

Published: July 12, 2024

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.

Journal: Oncoimmunology

Published: June 10, 2022

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.

Journal: Science (New York, N.Y.)

Published: September 01, 2021

MACSima imaging cyclic staining (MICS) technology reveals combinatorial target pairs for CAR T cell treatment of solid tumors.

MACSima imaging cyclic staining (MICS) technology reveals combinatorial target pairs for CAR T cell treatment of solid tumors.

Journal: Scientific reports

Published: August 18, 2021

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.

Journal: Nature

Published: April 09, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026